Frank M. Schabel

1.6k total citations
32 papers, 1.2k citations indexed

About

Frank M. Schabel is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Frank M. Schabel has authored 32 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Infectious Diseases. Recurrent topics in Frank M. Schabel's work include Computational Drug Discovery Methods (5 papers), HIV/AIDS drug development and treatment (5 papers) and Cancer therapeutics and mechanisms (4 papers). Frank M. Schabel is often cited by papers focused on Computational Drug Discovery Methods (5 papers), HIV/AIDS drug development and treatment (5 papers) and Cancer therapeutics and mechanisms (4 papers). Frank M. Schabel collaborates with scholars based in United States. Frank M. Schabel's co-authors include Glen J. Dixon, R W Brockman, John A. Montgomery, Lawrence E. Broder, Thomas P. Johnston, Stephen K. Carter, Robert W. Sidwell, Daniel P. Griswold, William M. Shannon and Thomas H. Corbett and has published in prestigious journals such as Nature, Science and JNCI Journal of the National Cancer Institute.

In The Last Decade

Frank M. Schabel

31 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frank M. Schabel United States 17 474 350 196 162 148 32 1.2k
Frederick E. Durr United States 16 484 1.0× 450 1.3× 199 1.0× 98 0.6× 89 0.6× 41 1.2k
A Goldin United States 19 478 1.0× 454 1.3× 157 0.8× 67 0.4× 36 0.2× 114 1.3k
Gerhard Zenke Switzerland 26 1.1k 2.4× 409 1.2× 248 1.3× 212 1.3× 170 1.1× 60 2.4k
George E. Foley United States 13 654 1.4× 390 1.1× 151 0.8× 157 1.0× 205 1.4× 17 1.6k
Peter R. Twentyman United Kingdom 22 787 1.7× 884 2.5× 96 0.5× 62 0.4× 127 0.9× 48 1.5k
A. Di Marco Italy 24 1.0k 2.1× 785 2.2× 318 1.6× 113 0.7× 40 0.3× 68 2.0k
Gary S. David United States 16 772 1.6× 230 0.7× 90 0.5× 71 0.4× 37 0.3× 41 1.7k
Glenn M. Swartz United States 21 975 2.1× 333 1.0× 116 0.6× 185 1.1× 92 0.6× 40 2.1k
Kenji Harada Japan 17 588 1.2× 462 1.3× 85 0.4× 111 0.7× 39 0.3× 46 1.5k
M. V. Pimm United Kingdom 29 769 1.6× 682 1.9× 119 0.6× 143 0.9× 52 0.4× 123 2.3k

Countries citing papers authored by Frank M. Schabel

Since Specialization
Citations

This map shows the geographic impact of Frank M. Schabel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank M. Schabel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank M. Schabel more than expected).

Fields of papers citing papers by Frank M. Schabel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank M. Schabel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank M. Schabel. The network helps show where Frank M. Schabel may publish in the future.

Co-authorship network of co-authors of Frank M. Schabel

This figure shows the co-authorship network connecting the top 25 collaborators of Frank M. Schabel. A scholar is included among the top collaborators of Frank M. Schabel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank M. Schabel. Frank M. Schabel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schabel, Frank M., Daniel P. Griswold, Thomas H. Corbett, & W R Laster. (1984). Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer. 54(S1). 1160–1167. 66 indexed citations
2.
Corbett, Thomas H., Wilbur R. Leopold, Donald J. Dykes, et al.. (1982). Toxicity and anticancer activity of a new triazine antifolate (NSC 127755).. PubMed. 42(5). 1707–15. 59 indexed citations
3.
Corbett, Thomas H., Daniel P. Griswold, Billy Roberts, & Frank M. Schabel. (1981). Absence of delayed lethality in mice treated with aclacinomycin A. Cancer Chemotherapy and Pharmacology. 6(2). 161–168. 13 indexed citations
4.
Shannon, William M. & Frank M. Schabel. (1980). Antiviral agents as adjuncts in cancer chemotherapy. Pharmacology & Therapeutics. 11(2). 263–390. 35 indexed citations
5.
Schabel, Frank M.. (1977). Rationale for adjuvant chemotherapy. Cancer. 39(6). 2875–2882. 65 indexed citations
6.
Schabel, Frank M.. (1977). Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer. 40(S1). 558–568. 55 indexed citations
7.
Brockman, R W, et al.. (1975). THE MECHANISM OF ACTION OF 3‐DEAZAURIDINE IN TUMOR CELLS SENSITIVE AND RESISTANT TO ARABINOSYLCYTOSINE*. Annals of the New York Academy of Sciences. 255(1). 501–521. 61 indexed citations
8.
Shannon, William M., R W Brockman, Louise Westbrook, Sue C. Shaddix, & Frank M. Schabel. (1974). Inhibition of Gross Leukemia Virus-Induced Plaque Formation in XC Cells by 3-Deazauridine2. JNCI Journal of the National Cancer Institute. 52(1). 199–205. 17 indexed citations
9.
Shannon, William M., Louise Westbrook, & Frank M. Schabel. (1974). Inhibition of Gross Murine Leukemia Virus Replication by Rifamycin SV and Certain of Its Derivatives in vitro. Intervirology. 3(1-2). 84–96. 5 indexed citations
10.
Rosen, Peter J., Seymour Perry, & Frank M. Schabel. (1970). Proliferative Capacity of Leukemic Cells in AKR Leukemia<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>. JNCI Journal of the National Cancer Institute. 45(6). 1169–78. 10 indexed citations
11.
Schabel, Frank M.. (1970). PURINE AND PYRIMIDINE NUCLEOSIDES AS ANTIVIRAL AGENTS—RECENT DEVELOPMENTS. Annals of the New York Academy of Sciences. 173(1). 215–220. 6 indexed citations
12.
Sidwell, Robert W., et al.. (1968). In Vivo Antiviral Properties of Biologically Active Compounds. Applied Microbiology. 16(2). 370–392. 70 indexed citations
13.
Sidwell, Robert W., et al.. (1968). Effects of a series of purine analogs on Friend leukemia virus infections in mice.. PubMed. 28(1). 35–40. 6 indexed citations
14.
Sidwell, Robert W., et al.. (1968). In Vivo Antiviral Properties of Biologically Active Compounds. Applied Microbiology. 16(2). 370–392. 51 indexed citations
15.
Sidwell, Robert W., et al.. (1965). In Vivo Antiviral Activity of 1,3-Bis(2-Chloroethyl)-1-Nitrosourea. Applied Microbiology. 13(4). 579–589. 4 indexed citations
16.
Sidwell, Robert W., et al.. (1965). In Vivo Antiviral Activity of 1,3-Bis(2-Chloroethyl)-1-Nitrosourea. Applied Microbiology. 13(4). 579–589. 6 indexed citations
17.
Griswold, Daniel P., et al.. (1963). Experimental Evaluation of Potential Anticancer Agents: XII. Quantitative Drug Response of the SA180, CA755, and Leukemia L1210 Systems to a “Standard List” of “Active” and “Inactive” Agents. Cancer Research. 23. 271–519. 10 indexed citations
18.
Montgomery, John A., Frank M. Schabel, & Howard E. Skipper. (1962). Experimental evaluation of potential anticancer agents. IX. The ribonucleosides and ribonucleotides of two purine antagonists.. PubMed. 22. 504–9. 16 indexed citations
19.
Laster, W R, et al.. (1961). Experimental evaluation of potential anticancer agents. IV. Host weight loss as it relates to false positives in drug evaluation.. PubMed. 21. 895–906. 8 indexed citations
20.
Skipper, Howard E. & Frank M. Schabel. (1952). Reversal of the growth inhibitory action of urethan by 2,6-diaminopurine. Archives of Biochemistry and Biophysics. 40(2). 476–478. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frederick E. Durr Breakdown of academic impact, for papers by A Goldin Breakdown of academic impact, for papers by Gerhard Zenke Breakdown of academic impact, for papers by George E. Foley Breakdown of academic impact, for papers by Peter R. Twentyman Breakdown of academic impact, for papers by A. Di Marco Breakdown of academic impact, for papers by Gary S. David Breakdown of academic impact, for papers by Glenn M. Swartz Breakdown of academic impact, for papers by Kenji Harada Breakdown of academic impact, for papers by M. V. Pimm
Rankless by CCL
2026